Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 15% in 2024 compared to 2023[18]. - The company's operating revenue for 2024 reached ¥2,016,975,873.58, representing a 4.32% increase compared to ¥1,933,504,352.30 in 2023[23]. - The net profit attributable to shareholders decreased by 11.77% to ¥661,129,436.27 in 2024 from ¥749,343,813.98 in 2023[23]. - The net profit after deducting non-recurring gains and losses fell by 17.00% to ¥603,843,535.48 in 2024 compared to ¥727,562,738.75 in 2023[23]. - The cash flow from operating activities decreased by 26.16% to ¥609,811,011.34 in 2024 from ¥825,875,198.80 in 2023[23]. - The total revenue for 2024 reached ¥2,016,975,873.58, representing a year-on-year increase of 4.32% compared to ¥1,933,504,352.30 in 2023[94]. - The revenue from the daily chemical industry was ¥1,164,229,146.51, accounting for 57.72% of total revenue, with a year-on-year growth of 7.49%[94]. - Online sales contributed ¥1,108,480,558.67, which is 54.96% of total revenue, showing a significant increase of 20.03% from the previous year[94]. - The offline sales decreased by 10.05% to ¥908,472,232.12, which is 45.04% of total revenue[94]. Market Strategy and Expansion - The company is focusing on expanding its market presence through new product launches and technological advancements in the medical device sector[18]. - The company is exploring strategic acquisitions to bolster its product offerings and market share in the cosmetic and medical device industries[18]. - The company is focusing on channel development, optimizing both online and offline sales strategies to drive revenue growth[55]. - The company is actively expanding its product matrix to include both Class II and Class III medical devices, enhancing its market position[69]. - The company plans to focus on green and sustainable product development as a core competitive dimension in response to evolving consumer demands[135]. - The company is expanding its market share in the sodium hyaluronate product segment through new formulations and product types[105]. - The company is expanding its product offerings in the aesthetic medicine market by developing a class III injectable filler product with improved structural stability and degradation resistance[104]. Research and Development - The company is investing in research and development for innovative skincare products aimed at addressing specific skin conditions[18]. - The company has established a new R&D center in Shanghai, enhancing its independent research capabilities and strategic layout[57]. - The company aims to strengthen its R&D capabilities through collaboration with universities and research institutions, focusing on new materials and technologies[57]. - The number of R&D personnel increased to 58 in 2024 from 27 in 2023, representing a growth of 114.81%[107]. - R&D investment amounted to ¥34,822,834.22 in 2024, up from ¥32,838,801.46 in 2023, with the proportion of R&D investment to operating revenue at 1.73%[107]. - The company has established a multi-omics database for medicinal plants, containing over 1,000 plant resources and 5,000-10,000 compound information entries, enhancing its research capabilities[105]. Product Development - The company launched multiple new products, including whitening masks and anti-wrinkle masks, to meet diverse consumer skincare needs[54]. - The company is focusing on the development of Class II and III medical devices, particularly in skin improvement and injection filling categories[57]. - The company is preparing to design and develop a sodium polyglutamate repair patch, which is expected to provide an 8-hour moisturizing effect and accelerate wound healing[104]. - The company has successfully developed a new NMN raw material, which has been registered with the National Cosmetics Raw Material Registration, registration number 20230044[105]. - The company is developing a new series of products based on Centella Asiatica extracts, which are expected to provide strong moisturizing and soothing effects[105]. Corporate Governance - The governance structure includes a clear division of responsibilities among the shareholders' meeting, board of directors, supervisory board, and management, ensuring compliance with relevant laws and regulations[163]. - The board of directors consists of 5 members, including 2 independent directors, meeting legal requirements and ensuring diligent oversight[166]. - The supervisory board has 3 members, including 1 employee representative, fulfilling its duties to protect the rights of shareholders[167]. - The company actively engages with stakeholders to balance interests and fulfill social responsibilities[168]. - The company adheres to the information disclosure obligations as per relevant laws and regulations, ensuring accurate and timely information dissemination to all shareholders[169]. Future Outlook - The company has outlined a future outlook that includes potential risks and growth opportunities in the upcoming fiscal year[6]. - The company has set a performance guidance for 2025, projecting a revenue growth of 10% to 12%[18]. - The company’s future outlook remains positive, with expectations for growth driven by new product launches and market opportunities[183]. - The company plans to continue its market expansion strategy, focusing on enhancing its product offerings and technological advancements[183].
敷尔佳(301371) - 2024 Q4 - 年度财报